VANCOUVER, June 13, 2018 /CNW/ - Zecotek Photonics Inc.
("Zecotek" or the
"Company") (TSX-V: ZMS) (Frankfurt:
W1I) (OTCPK: ZMSPF), a developer of leading-edge photonics
technologies for healthcare, industrial and scientific markets, is
pleased to announce the single largest purchase order of
US$5,000,000 for its patented LFS
scintillation crystals through a distribution partner in
China. The crystals will be used
for positron emission tomography (PET) medical scanning
equipment.
"2018 will be a transformative year for Zecotek's medical
imaging business," said Dr. A.F. Zerrouk, Chairman, President, and
CEO of Zecotek Photonics Inc. "This purchase order of US$5 million represents more revenue than we have
achieved previously in an entire year. The order also demonstrates
the success of the patient and systematic approach we have taken in
the Chinese marketplace. Our initiatives have established a strong
foothold in China by creating key
distribution partnerships, building a talented local sales team,
and, as recently announced, installing our own state-of-the-art
crystal production facility. The large order comes from one of our
key sales channel partners for components related to the PET/CT
medical imaging industry. The first shipment of LFS crystals is
expected to be completed in the next 30 days, with the crystals
coming from our current inventory. The remaining shipments will
take place over the next 12 months and will be supplied by our new
crystal production facility in Shanghai. We will continue to aggressively
expand our sales opportunities in China and elsewhere and look forward to
reporting further results."
Zecotek's LFS series of scintillation crystals are known to be
uniquely qualified for components in PET medical scanners. LFS
crystals have the fastest decay parameter in their category, the
best energy resolution and competitive pricing, which are key
attributes for the new configurations of high resolution Time Of
Flight PET scanners. PET OEMs have conducted comparative tests with
other many other scintillation materials, and recognize Zecotek's
LFS crystals to be superior for specific designs of PET medical
scanners.
Zecotek is focused on of becoming a leading supplier of
scintillation crystals and other the key photonic components in
China and around the world.
About Zecotek
Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I; OTCPK: ZMSPF) is a photonics
technology company developing high-performance scintillation
crystals, photo detectors, positron emission tomography scanning
technologies, 3D auto-stereoscopic displays, 3D metal printing, and
lasers for applications in medical, high-tech and industrial
sectors. Founded in 2004, Zecotek operates three divisions: Imaging
Systems, Optronics Systems and 3D Display Systems with labs located
in Canada, Korea, Russia, Singapore and U.S.A. The management team is focused on
building shareholder value by commercializing over 50 patented and
patent pending novel photonic technologies directly and through
strategic alliances with Hamamatsu Photonics (Japan), the European Organization for Nuclear
Research (Switzerland), NuCare
Medical Systems (South Korea), the
University of Washington (United States), and National NanoFab Center
(South Korea). For more
information visit http://www.zecotek.com and follow @zecotek on
Twitter.
This press release may contain forward-looking statements that
are based on management's expectations, estimates, projections and
assumptions. These statements are not guarantees of future
performance and involve certain risks and uncertainties, which are
difficult to predict. Therefore, actual future results and trends
may differ materially from what may have been stated.
Neither the TSX Venture Exchange nor its Regulation Service
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of the content of this news release. If you would like to
receive news from Zecotek in the future please visit the corporate
website at http://www.zecotek.com.
SOURCE Zecotek Photonics Inc.
